- Home
- SYK vs GILD Comparison
SYK vs GILD Comparison
Compare SYK & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYK
- GILD
- Stock Information
- Founded
- SYK 1941
- GILD 1987
- Country
- SYK United States
- GILD United States
- Employees
- SYK N/A
- GILD N/A
- Industry
- SYK Medical/Dental Instruments
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYK Health Care
- GILD Health Care
- Exchange
- SYK Nasdaq
- GILD Nasdaq
- Market Cap
- SYK 139.4B
- GILD 113.0B
- IPO Year
- SYK N/A
- GILD 1992
- Fundamental
- Price
- SYK $396.49
- GILD $98.89
- Analyst Decision
- SYK Buy
- GILD Buy
- Analyst Count
- SYK 20
- GILD 26
- Target Price
- SYK $419.37
- GILD $98.58
- AVG Volume (30 Days)
- SYK 1.6M
- GILD 7.1M
- Earning Date
- SYK 01-28-2025
- GILD 02-11-2025
- Dividend Yield
- SYK 0.86%
- GILD 3.15%
- EPS Growth
- SYK N/A
- GILD N/A
- EPS
- SYK 7.76
- GILD 0.10
- Revenue
- SYK $22,595,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- SYK $9.13
- GILD $6.48
- Revenue Next Year
- SYK $7.83
- GILD $0.37
- P/E Ratio
- SYK $50.55
- GILD $1,009.07
- Revenue Growth
- SYK 10.23
- GILD 3.31
- 52 Week Low
- SYK $314.93
- GILD $62.07
- 52 Week High
- SYK $406.19
- GILD $99.45
- Technical
- Relative Strength Index (RSI)
- SYK 64.09
- GILD 70.70
- Support Level
- SYK $387.00
- GILD $91.84
- Resistance Level
- SYK $400.56
- GILD $99.45
- Average True Range (ATR)
- SYK 7.39
- GILD 1.84
- MACD
- SYK 0.73
- GILD 0.63
- Stochastic Oscillator
- SYK 71.57
- GILD 93.51
About SYK Stryker Corporation
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).